Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00583791 · ClinicalTrials.gov registry record · NA
Closure of Muscular Ventricular Septal Defects With The AMPLATZER™ Muscular VSD Occluder
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 91
- Enrollment target
NCT00583791: Completed NA study, sponsored by Abbott Medical Devices.
NCT00583791 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 91 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00583791, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 91 participants
- Enrollment target
Study Summary
The objective is to investigate the safety of the AMPLATZER Muscular VSD Occluder for the treatment of muscular ventricular septal defects, which are hemodynamically significant and are either isolated or in conjunction with other congenital heart defects in infants and children.
Primary Outcome
Closure of muscular ventricular septal defect with the AMPLATZER Muscular VSD Occluder
Interventions
- DEVICE Device closure with the AMPLATZER Muscular VSD Occluder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2000-07 |
| Est. Completion | 2009-11 |
| Phase | NA |
What the finished NCT00583791 record still lists
NCT00583791 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Device closure with the AMPLATZER Muscular VSD Occluder is the first listed.
NCT00583791 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00583791 about?
NCT00583791 is a clinical study titled "Closure of Muscular Ventricular Septal Defects With The AMPLATZER™ Muscular VSD Occluder". The objective is to investigate the safety of the AMPLATZER Muscular VSD Occluder for the treatment of muscular ventricular septal defects, which are hemodynamically significant and are either isolated or in conjunction with other congenital heart defects in infants and children.
What is the current status of trial NCT00583791?
This trial is currently completed. It is a NA study. The enrollment target is 91 participants. The study started on 2000-07. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00583791?
The interventions under investigation include: Device closure with the AMPLATZER Muscular VSD Occluder (DEVICE).
Who is sponsoring clinical trial NCT00583791?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00583791's enrollment target sits among peer trials
91 939th of 2000 higher than 1,060 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia